OR WAIT null SECS
January 05, 2018
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
January 04, 2018
The contract manufacturing company has completed construction on a new aseptic fill/finish facility in Wuxi, China.
December 20, 2017
FDA has approved a new gene therapy for treating patients born with a rare, inherited vision loss.
December 19, 2017
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
December 14, 2017
Children with a rare brainstem-based cancer might be helped by a new immunotherapy that targets a mutated protein found exclusively in cancer cells.
December 13, 2017
The companies will co-develop and co-commercialize the lead candidate generated from their earlier collaboration to treat genetic blood disorders.
December 08, 2017
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
December 01, 2017
The company has opened a new California facility that, combined with its existing site in Foster City, CA, will quadruple its laboratory footprint for gene therapy products.
Lonza has entered into strategic license agreements for exclusive rights to a gene-therapy platform for developing treatments for hearing and balance disorders.
November 02, 2017
The companies will collaborate to develop and manufacture Grid’s lead therapeutic candidate for the treatment of solid tumors.